Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Wolf

Showing results (251-260 of 331) with videos related to

Pageof 34
Sort By:
Wiener Klinische Wochenschrift|October 12, 2010
First annual report of the Austrian CML registryStefan Schmidt, Dominik Wolf, Josef Thaler, et al.
Frontiers in Aging Neuroscience|September 11, 2025
Cognitive training gain transfer in cognitively healthy aging: per protocol results of the German AgeGain studyFlorian U Fischer, Bianca Kollmann, Dominik Wolf, et al.
NPJ Precision Oncology|April 22, 2025
Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapiesMarwa Abdel Hamid, Lorenz M Pammer, Silvia Oberparleiter, et al.
Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.
Haematologica|April 19, 2012
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialAndreas L Petzer, Dominic Fong, Thomas Lion, et al.
Leukemia|August 16, 2022
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.
Haematologica|February 11, 2010
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" studyAndreas L Petzer, Dominik Wolf, Dominic Fong, et al.
European Journal of Haematology|July 31, 2018
Recommendations for the diagnosis and treatment of patients with polycythaemia veraAntónia Hatalova, Jiri Schwarz, Mirjana Gotic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.
Journal of Cancer Research and Clinical Oncology|August 7, 2023
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancerViktoria Florentine Koehler, Josefine Achterfeld, Natalie Sandner, et al.
Pageof 34

Showing results (251-260 of 331) with videos related to

Sort By:
Pageof 34
Wiener Klinische Wochenschrift|October 12, 2010
First annual report of the Austrian CML registryStefan Schmidt, Dominik Wolf, Josef Thaler, et al.
Frontiers in Aging Neuroscience|September 11, 2025
Cognitive training gain transfer in cognitively healthy aging: per protocol results of the German AgeGain studyFlorian U Fischer, Bianca Kollmann, Dominik Wolf, et al.
NPJ Precision Oncology|April 22, 2025
Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapiesMarwa Abdel Hamid, Lorenz M Pammer, Silvia Oberparleiter, et al.
Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.
Haematologica|April 19, 2012
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialAndreas L Petzer, Dominic Fong, Thomas Lion, et al.
Leukemia|August 16, 2022
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.
Haematologica|February 11, 2010
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" studyAndreas L Petzer, Dominik Wolf, Dominic Fong, et al.
European Journal of Haematology|July 31, 2018
Recommendations for the diagnosis and treatment of patients with polycythaemia veraAntónia Hatalova, Jiri Schwarz, Mirjana Gotic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.
Journal of Cancer Research and Clinical Oncology|August 7, 2023
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancerViktoria Florentine Koehler, Josefine Achterfeld, Natalie Sandner, et al.
Pageof 34